

consolidated financial statements

390	Consolidated Income Statement
391	Consolidated Statement of Comprehensive Income
392	Consolidated Balance Sheet
393	Consolidated Cash Flow Statement
394	Consolidated Statement of Changes in Net Equity
395	Notes to the Consolidated Financial Statements
395	General Disclosures
402	Group Structure
410	Operating Activities
431	Operating Assets, Liabilities, and Contingent Liabilities
454	Employees
465	Capital Structure, Investments and Financing Assets
506	Other Disclosures
509	Scope of Consolidation

Consolidated Income Statement

€ million	Note	2024	2023
Net sales	9	21,156	20,993
Cost of sales	10	-8,671	-8,600
Gross profit		12,485	12,392
Marketing and selling expenses	11	-4,536	-4,510
Administration expenses		-1,370	-1,392
Research and development costs	12	-2,279	-2,445
Impairment losses and reversals of impairment losses on financial assets (net)	42	-8	-51
Other operating income	13	269	445
Other operating expenses	14	-915	-830
Operating result (EBIT)¹		3,645	3,609
Finance income	40	200	197
Finance costs	40	-309	-322
Profit before income tax		3,536	3,484
Income tax	15	-751	-650
Profit after tax		2,786	2,834
thereof: attributable to shareholders of Merck KGaA, Darmstadt, Germany (net income)		2,777	2,824
thereof: attributable to non-controlling interests	34	9	10
Earnings per share (in €)	17		
Basic		6.39	6.49
Diluted		6.39	6.49

¹ Not defined by International Financial Reporting Standards (IFRS).

Consolidated Statement of Comprehensive Income

€ million	Note	2024	2023
Profit after tax		2,786	2,834
Items of other comprehensive income that will not be reclassified to profit or loss in subsequent periods			
Net defined benefit liability	33		
Changes in remeasurement		179	-236
Tax effect		-89	48
Changes recognized in equity		90	-187
Equity instruments	34		
Fair value adjustments		37	158
Tax effect		-6	2
Changes recognized in equity		30	160
		121	-28
Items of other comprehensive income that may be reclassified to profit or loss in subsequent periods			
Cash flow hedge reserve	39		
Fair value adjustments		92	98
Reclassification to profit or loss		-149	-95
Reclassification to assets		-	-
Tax effect		5	-5
Changes recognized in equity		-52	-2
Cost of cash flow hedge reserve	39		
Fair value adjustments		-	-17
Reclassification to profit or loss		-2	22
Reclassification to assets		-	-
Tax effect		-	-
Changes recognized in equity		-2	5
Currency translation difference			
Changes taken directly to equity		1,444	-1,003
Reclassification to profit or loss		-15	-15
Changes recognized in equity		1,429	-1,018
		1,375	-1,015
Other comprehensive income		1,496	-1,043
Comprehensive income		4,282	1,791
thereof: attributable to shareholders of Merck KGaA, Darmstadt, Germany		4,272	1,783
thereof: attributable to non-controlling interests	34	9	8

Consolidated Balance Sheet

€ million	Note	Dec. 31, 2024	Dec. 31, 2023
Non-current assets			
Goodwill	18	19,152	17,845
Other intangible assets	19	6,282	6,551
Property, plant and equipment	20	10,025	9,056
Investments accounted for using the equity method		3	3
Non-current receivables	25	27	28
Other non-current financial assets	36	1,172	981
Other non-current non-financial assets	22	134	115
Non-current income tax receivables	15	9	9
Deferred tax assets	15	1,312	1,514
		38,116	36,102
Current assets			
Inventories	24	4,484	4,637
Trade and other current receivables	25	3,947	4,004
Contract assets	26	132	104
Other current financial assets	36	642	499
Other current non-financial assets	22	621	633
Current income tax receivables	15	512	473
Cash and cash equivalents	35	2,517	1,982
Assets held for sale	6	597	62
		13,450	12,393
Total assets		51,567	48,495
Total equity	34		
Equity capital		565	565
Capital reserves		3,814	3,814
Retained earnings		22,086	20,228
Gains/losses recognized in equity		3,448	2,073
Equity attributable to shareholders of Merck KGaA, Darmstadt, Germany		29,912	26,680
Non-controlling interests		75	75
		29,988	26,754
Non-current liabilities			
Non-current provisions for employee benefits	33	1,956	2,192
Other non-current provisions	27	257	277
Non-current financial debt	37	6,997	9,239
Other non-current financial liabilities	38	135	147
Other non-current non-financial liabilities	29	12	17
Non-current income tax liabilities	15	36	39
Deferred tax liabilities	15	892	1,130
		10,285	13,042
Current liabilities			
Current provisions for employee benefits	33	66	83
Current provisions	27	505	575
Current financial debt	37	3,304	702
Other current financial liabilities	38	1,030	1,005
Trade and other current payables	30	2,275	2,545
Refund liabilities	9	869	877
Current income tax liabilities	15	1,527	1,433
Other current non-financial liabilities	29	1,562	1,479
Liabilities directly related to assets held for sale	6	157	-
		11,294	8,699
Total equity and liabilities		51,567	48,495

Consolidated Cash Flow Statement

€ million	Note	2024	2023
Profit after tax		2,786	2,834
Depreciation/amortization/impairment losses/reversals of impairment losses		2,134	1,880
Changes in inventories		36	-89
Changes in trade accounts receivable		79	-8
Changes in trade accounts payable/refund liabilities		-178	-43
Changes in provisions		62	188
Changes in other assets and liabilities		-309	-755
Neutralization of gains/losses on disposal of fixed assets and other disposals		-2	-150
Other non-cash income and expenses		-22	-72
Operating Cash Flow	16	4,586	3,784
Payments for investments in intangible assets		-482	-216
Proceeds from the disposal of intangible assets		18	136
Payments for investments in property, plant and equipment		-1,702	-1,807
Proceeds from the disposal of property, plant and equipment		27	19
Payments for investments in other assets ¹		-2,251	-3,031
Proceeds from the disposal of other assets ¹		2,107	3,021
Payments for acquisitions less acquired cash and cash equivalents (net)		-774	-12
Proceeds from divestments		7	-
Investing Cash Flow	23	-3,050	-1,892
Dividend payments to shareholders of Merck KGaA, Darmstadt, Germany		-284	-284
Dividend payments to non-controlling interests		-9	-12
Profit withdrawal by E. Merck KG, Darmstadt, Germany		-747	-868
Proceeds from new borrowings of financial debt from E. Merck KG, Darmstadt, Germany, and E. Merck Beteiligungen KG, Darmstadt, Germany, a related party of E. Merck KG, Darmstadt, Germany		683	697
Repayment of financial debt to E. Merck KG, Darmstadt, Germany, and E. Merck Beteiligungen KG, Darmstadt, Germany, a related party of E. Merck KG, Darmstadt, Germany		-453	-420
Proceeds from new borrowings of other current and non-current financial debt		2,113	519
Repayment of other current and non-current financial debt		-2,290	-1,364
Financing Cash Flow	41	-985	-1,732
Changes in cash and cash equivalents		551	160
Changes in cash and cash equivalents due to currency translation		-16	-31
Cash and cash equivalents as of January 1		1,982	1,854
Cash and cash equivalents as of December 31 (consolidated balance sheet)	35	2,517	1,982

¹ Prior-year figures have been adjusted, see note (2) "[Reporting principles](#)".

Consolidated Statement of Changes in Net Equity

For details see Note (34) [“Equity”](#).

€ million	Equity capital	Capital reserves	Retained earnings	Gains/losses recognized in equity	Equity attributable to shareholders of Merck KGaA, Darmstadt, Germany	Non-controlling interests	Total equity
Jan. 1, 2023	565	3,814	18,463	3,086	25,927	78	26,005
Profit after tax	–	–	2,824	–	2,824	10	2,834
Gains/losses recognized in equity	–	–	-28	-1,013	-1,041	-2	-1,043
Comprehensive income	–	–	2,796	-1,013	1,783	8	1,791
Dividend payments	–	–	-284	–	-284	-16	-300
Capital increases	–	–	–	–	–	5	5
Profit transfer to/from E. Merck KG, Darmstadt, Germany, including changes in reserves	–	–	-746	–	-746	–	-746
Transactions with no change of control	–	–	-1	–	-1	–	–
Change in scope of consolidation/Other	–	–	–	–	–	–	–
Dec. 31, 2023	565	3,814	20,228	2,073	26,680	75	26,754

€ million	Equity capital	Capital reserves	Retained earnings	Gains/losses recognized in equity	Equity attributable to shareholders of Merck KGaA, Darmstadt, Germany	Non-controlling interests	Total equity
Jan. 1, 2024	565	3,814	20,228	2,073	26,680	75	26,754
Profit after tax	–	–	2,777	–	2,777	9	2,786
Gains/losses recognized in equity	–	–	121	1,375	1,496	–	1,496
Comprehensive income	–	–	2,897	1,375	4,272	9	4,282
Dividend payments	–	–	-284	–	-284	-9	-293
Capital increases	–	–	–	–	–	1	1
Profit transfer to/from E. Merck KG, Darmstadt, Germany, including changes in reserves	–	–	-755	–	-755	–	-755
Transactions with no change of control	–	–	–	–	–	–	–
Change in scope of consolidation/Other	–	–	–	–	–	–	–
Dec. 31, 2024	565	3,814	22,086	3,448	29,912	75	29,988